Alice Wang

ORCID: 0000-0003-4468-9367 · 2 papers in corpus
2023
·doi:10.21203/rs.3.rs-3487715/v1

Abstract Refractoriness to initial chemotherapy and relapse after remission are the main obstacles to cure in T-cell Acute Lymphoblastic Leukemia (T-ALL). Biomarker guided risk stratification and targeted therapy have the potential to impr…

article 2021
F&S reports ·doi:10.1016/j.xfre.2021.05.004

OBJECTIVE: To determine if coexisting adenomyosis limits the efficacy of elagolix, an oral gonadotropin-releasing hormone antagonist, with hormonal add-back therapy in reducing heavy menstrual bleeding in women with uterine fibroids. DESIGN…